Protalix BioTherapeutics (PLX) Operating Margin (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Operating Margin of 62.65% for Q1 2026, up 10364.0% year-over-year from N/an in Q1 2025, and up 222.7% quarter-over-quarter from 51.06% in Q4 2025.
Protalix BioTherapeutics (PLX) Operating Margin (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Operating Margin history runs 17 years deep, the most recent figure standing at 62.65% for Q1 2026.
- In Q1 2026, Operating Margin rose 10364.0% year-over-year to 62.65%; the TTM figure through Mar 2026 stood at 25.91% (up 1817.0% YoY), while the FY2025 annual figure was 10.43%, down 1776.0% from the prior year.
- Operating Margin for Q1 2026 stood at 62.65%, up from 51.06% in the prior quarter.
- The five-year high for Operating Margin was 62.65% in Q1 2026, with the low at 129.56% in Q1 2024.
- The 5-year median for Operating Margin is 18.24% (2023), against an average of 15.33%.
- The sharpest annual moves came in 2023 and 2024: Operating Margin jumped 12133 bps in 2023, then plunged 10392 bps in 2024.
- Protalix BioTherapeutics' Operating Margin stood at 28.95% in 2022, then tumbled by 85 bps to 53.55% in 2023, then jumped by 174 bps to 39.57% in 2024, then plunged by 229 bps to 51.06% in 2025, then jumped by 223 bps to 62.65% in 2026.
- Business Quant data shows PLX's Operating Margin at 62.65% in Q1 2026, 51.06% in Q4 2025, and 11.94% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Protalix BioTherapeutics | 192.37 Mn | 151.71 Mn | 12.13 Mn | 23.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.48% |
| Mar 31, 2026 | 62.65% |
| Dec 31, 2025 | -51.06% |
| Sep 30, 2025 | 11.94% |
| Jun 30, 2025 | 7.48% |
| Mar 31, 2025 | -40.99% |
| Dec 31, 2024 | 39.57% |
| Sep 30, 2024 | 22.22% |
| Jun 30, 2024 | -18.01% |
| Mar 31, 2024 | -129.56% |
| Dec 31, 2023 | -53.55% |
| Sep 30, 2023 | -18.24% |
| Jun 30, 2023 | 58.22% |
| Mar 31, 2023 | -25.65% |
| Dec 31, 2022 | -28.95% |
| Sep 30, 2022 | -22.03% |
| Jun 30, 2022 | -63.11% |
| Mar 31, 2022 | -11.63% |
| Dec 31, 2021 | -66.74% |
| Sep 30, 2021 | -15.64% |